Targeting GHSR1a-DRD1 heteromers with a bitopic agonist could be an important preventative treatment for Alzheimer’s disease, although the effects on food intake and insulin secretion would need to be assessed carefully. This evidence concerns the gene DRD1 and early-onset autosomal dominant Alzheimer disease.